Latest Insider Transactions at G1 Therapeutics, Inc. (GTHX)
This section provides a real-time view of insider transactions for G1 Therapeutics, Inc. (GTHX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of G1 Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of G1 Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 13
2024
|
Terry L Murdock Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
8,151
-7.86%
|
$32,604
$4.79 P/Share
|
|
May 13
2024
|
John V. Umstead Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,151
-5.05%
|
$32,604
$4.79 P/Share
|
|
May 13
2024
|
Mark Avagliano Chief Business Officer |
SELL
Open market or private sale
|
Direct |
8,151
-3.74%
|
$32,604
$4.79 P/Share
|
|
May 13
2024
|
Rajesh Malik Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,151
-4.8%
|
$32,604
$4.79 P/Share
|
|
May 13
2024
|
John E. (Jack) Bailey Jr. President and CEO |
SELL
Open market or private sale
|
Direct |
37,258
-7.61%
|
$149,032
$4.79 P/Share
|
|
Mar 20
2024
|
Monica R. Thomas Chief Legal & People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+24.49%
|
-
|
|
Mar 20
2024
|
John V. Umstead Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+18.85%
|
-
|
|
Mar 20
2024
|
Mark Avagliano Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+31.46%
|
-
|
|
Mar 18
2024
|
John V. Umstead Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,547
-5.02%
|
$19,641
$3.02 P/Share
|
|
Feb 12
2024
|
Rajesh Malik Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
28,600
-14.41%
|
$114,400
$4.62 P/Share
|
|
Feb 12
2024
|
Rajesh Malik Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
28,600
+12.59%
|
$0
$0.3 P/Share
|
|
Jan 04
2024
|
Terry L Murdock Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
721
-0.69%
|
$1,442
$2.94 P/Share
|
|
Jan 04
2024
|
Mark Avagliano Chief Business Officer |
SELL
Open market or private sale
|
Direct |
721
-0.61%
|
$1,442
$2.94 P/Share
|
|
Jan 04
2024
|
Rajesh Malik Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
721
-0.42%
|
$1,442
$2.94 P/Share
|
|
Jan 04
2024
|
John V. Umstead Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
111
-0.09%
|
$222
$2.94 P/Share
|
|
Jan 03
2024
|
Terry L Murdock Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,019
-1.41%
|
$9,057
$3.12 P/Share
|
|
Jan 03
2024
|
Terry L Murdock Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,300
+25.78%
|
-
|
|
Jan 03
2024
|
Mark Avagliano Chief Business Officer |
SELL
Open market or private sale
|
Direct |
3,360
-1.38%
|
$10,080
$3.12 P/Share
|
|
Jan 03
2024
|
Mark Avagliano Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
44,760
+26.85%
|
-
|
|
Jan 03
2024
|
John E. (Jack) Bailey Jr. President and CEO |
SELL
Open market or private sale
|
Direct |
11,686
-1.17%
|
$35,058
$3.12 P/Share
|
|
Jan 03
2024
|
John E. (Jack) Bailey Jr. President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
100,700
+16.73%
|
-
|
|
Jan 03
2024
|
Andrew Perry Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,413
-1.35%
|
$7,239
$3.12 P/Share
|
|
Jan 03
2024
|
Andrew Perry Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,570
+27.27%
|
-
|
|
Jan 03
2024
|
Rajesh Malik Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,019
-0.87%
|
$9,057
$3.12 P/Share
|
|
Jan 03
2024
|
Rajesh Malik Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,300
+17.68%
|
-
|
|
Jan 03
2024
|
Monica R. Thomas Chief Legal & People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,975
+26.36%
|
-
|
|
Jan 03
2024
|
John V. Umstead Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
632
-0.24%
|
$1,896
$3.12 P/Share
|
|
Jan 03
2024
|
John V. Umstead Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,300
+22.14%
|
-
|
|
Jan 02
2024
|
John E. (Jack) Bailey Jr. President and CEO |
SELL
Open market or private sale
|
Direct |
32,983
-7.61%
|
$98,949
$3.27 P/Share
|
|
Dec 11
2023
|
Rajesh Malik Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
33,839
-10.96%
|
$101,517
$3.54 P/Share
|
|
Dec 11
2023
|
Rajesh Malik Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
33,839
+9.83%
|
$0
$0.35 P/Share
|
|
Aug 08
2023
|
Mark A. Velleca |
SELL
Open market or private sale
|
Direct |
60,000
-17.67%
|
$120,000
$2.01 P/Share
|
|
Aug 08
2023
|
Mark A. Velleca |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+13.54%
|
$0
$0.35 P/Share
|
|
Jul 05
2023
|
John E. (Jack) Bailey Jr. President and CEO |
SELL
Open market or private sale
|
Direct |
2,719
-0.62%
|
$5,438
$2.45 P/Share
|
|
Jul 05
2023
|
Rajesh Malik Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,361
-0.99%
|
$2,722
$2.45 P/Share
|
|
Jul 05
2023
|
Terry L Murdock Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,361
-1.91%
|
$2,722
$2.45 P/Share
|
|
Jul 05
2023
|
Andrew Perry Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
355
-0.63%
|
$710
$2.45 P/Share
|
|
Jun 15
2023
|
Garry A Nicholson |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+29.08%
|
-
|
|
Jun 15
2023
|
Alicia Secor |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+33.33%
|
-
|
|
Jun 15
2023
|
Jacks Lee |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+50.0%
|
-
|
|
Jun 15
2023
|
Glenn P Muir |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+4.87%
|
-
|
|
Jun 15
2023
|
Cynthia Schwalm |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+27.86%
|
-
|
|
Jun 15
2023
|
Norman Sharpless |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+50.0%
|
-
|
|
May 22
2023
|
Monica R. Thomas Chief Legal & People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+49.91%
|
-
|
|
May 10
2023
|
John V. Umstead Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+27.16%
|
-
|
|
May 10
2023
|
Rajesh Malik Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+20.26%
|
-
|
|
May 10
2023
|
Mark Avagliano Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+31.21%
|
-
|
|
May 10
2023
|
Terry L Murdock Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+32.88%
|
-
|
|
May 10
2023
|
John E. (Jack) Bailey Jr. President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
160,000
+26.83%
|
-
|
|
May 10
2023
|
Andrew Perry Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+38.34%
|
-
|